Chronic cardiac failure in the XXI century

Abstract


Wide clinical application of modern prophylactic, diagnostic and therapeutic methods has significantly improved clinical outcomes of cardiovascular disorders. However, much progress is not seen in survival of patients with chronic cardiac failure (CCF). Three possible causes of this situation are analysed: absence of evidence base in the treatment of CCF patients free of systolic dysfunction, difficulties in management of patients with end-stage CCF, need in new markers of CCF. Approaches to solution of these problems and CCF treatment optimization in general are discussed.

About the authors

Sergey Nikolaevich Tereshchenko

Igor' Vital'evich Zhirov

S N Tereschenko

Russian Cardiological Research Center, Moscow

Russian Cardiological Research Center, Moscow

I V Zhirov

Russian Cardiological Research Center, Moscow

Russian Cardiological Research Center, Moscow

References

  1. Heart Stroke and Disease Statistics. Update 2010. Доступно на http://www.americanheart.org/downloadable/heart/ 1265665152970DS-3241%20HeartStrokeUpdate_2010.pdf
  2. Российский статистический ежегодник-2010. Доступно на http://www.gks.ru/bgd/regl/b10_13/Main.htm
  3. Никулина Н. Н., Якушин С. С., Бойцов С. А. и др. Проблемы статистической регистрации смертности от ХСН в Российской Федерации. В кн.: Тезисы III Конгресса общества специалистов по сердечной недостаточности "Сердечная недостаточность 2008".
  4. Фомин И. В., Беленков Ю. Н., Мареев В. Ю. и др. Распространенность хронической сердечной недостаточности в европейской части Российской Федерации - данные ЭПОХА-ХСН. Сердечн. недостат. 2006; 7(3): 112-115.
  5. Фомин И. В. Результаты 9-летнего наблюдения больных, включенных в эпидемиологическое исследование хронической сердечной недостаточности в Европейской части Российской Федерации - ЭПОХА-ХСН. В кн.: Тезисы III конгресса общества специалистов по сердечной недостаточности "Сердечная недостаточность 2008".
  6. Агеев Ф. Т. Диастолическая сердечная недостаточность: 10 лет знакомства. Сердеч. недостат. 2010; 11[1(57)]: 69-76.
  7. ESC Cuidelines for the diagnosis and treatment of acute and chronic heart failure 2008. Eur. Heart J. 2008; 29: 2388-2442.
  8. Focused Update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure Adults. Circulation 2009; 119; 1977-20l6.
  9. Национальные рекомендации ВНОК и ОССН по диагностике и лечению ХСН (третий пересмотр), 2009. Доступно на http://medic.ossn.ru/upload/ossn_pdf/Recomend/Guidelines%20SSHF%20rev.3.01%202010.pdf
  10. Sanderson J. E. Heart failure with a normal ejection fraction. Heart 2007; 93: 155-158.
  11. Owan T., Hodge D., Herges R. et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N. Engl. J. Med. 2006; 355: 251-259.
  12. Persson H. Investigators of the CHARM Echocardiographic Substudy-CHARMES. Diastolic dysfunction in heart failure with preserved systolic function: need for objective evidence: results from the CHARM Echocardiographic Substudy- CHARMES. J. Am. Coll. Cardiol. 2007; 49: 687-694.
  13. Беленков Ю. Н., Агеев Ф. Т., Мареев В. Ю. Знакомьтесь: диастолическая сердечная недостаточность. Сердеч. недостат. 2000; 1(2): 40-44.
  14. De Keulenaer G. W., Brutsaert D. L. Diastolic heart failure: a separate disease or selection bias? Progr. Cardiovasc. Dis. 2007; 49: 275-283.
  15. Cleland J., Tendera M., Adamus J. et al. The perindopril in elderly people with chronic heart faiure (PEP-CHF) study. Eur. Heart J. 2006; 27: 2338-2345.
  16. Yusuf S. Effects of candesartan in patients with chronic heart failure and preserved left ventricular systolic function: the CHARM-Preserved trial. Lancet 2003; 362: 777-781.
  17. Massie B. M., Carson P. E., McMurray J. J. et al. Irbesartan in patients with heart failure and preserved ejection fraction. N. Engl. J. Med. 2008; 359: 2456-2467.
  18. Aronow W. S. Effect of propranolol versus no propranolol on total mortality plus non fatal myocardial infraction in older patients with prior myocardial infarction, congestive heart failure, and left ventricular ejection fraction 40% treated with diuretics plus angiotensin-converting enzyme inhibitors. Am. J. Cardiol. 1997; 80: 207-209.
  19. Dobre D. Prescription of beta-blockers in patients with advanced heart failure and preserved left ventricular ejection fraction. Clinical implications and survival. Eur. J. Heart Fail. 2007; 9: 280-289.
  20. Massie B. M. Comparison of outcomes and usefulness of carvedilol across a spectrum of left ventricular ejection fractions in patients with heart failure in clinical practice. Am. J. Cardiol. 2007; 99: 1263-1268.
  21. Lund L., Matthews J., Aaronson K. Patient selection for left ventricular assist devices. Eur. J. Heart Fail. 2010; 12: 434- 443.
  22. Deng M. C. Orthotopic heart transplantation: highlights and limitations. Surg. Clin. N. Am. 2004; 84: 243-255.
  23. Taylor D. O., Stehlik J., Edwards L. B. et al. Registry of the International Society for Heart and Lung Transplantation: twenty-sixth official adult heart transplantation report-2009. J. Heart Lung Transplant. 2009; 28: 1007-1022.
  24. Hamour I. M., Khaghani A., Kanagala P. K. et al. Current outcome of heart transplantation: a 10-year single centre perspective and review - QJM. Nov. 2010; doi: 10.1093/qjmed/ hcq205.
  25. Slaughter M., Pagani F., Rogers J. et al. Clinical management of continuous-flow left ventricular assist devices in advanced heart failure. J. Heart Lung Transplant. 2010; 29: S1-S39.
  26. Warner-Stevenson L. The evolving role of mechanical circulatory support in advanced heart failure. In: Frazier O., Kirklin J. (eds.) ISHLT monograph series 1, mechanical circulatory support. Burlington, MA: Elsevier Inc; 2006. 181-203.
  27. Rogers J. G., Butler J., Lansman S. L. et al. Chronic mechanical circulatory support for inotrope-dependent heartfailure patients who are not transplant candidates: results of the INTrEPID Trial. J. Am. Coll. Cardiol. 2007; 50: 741-747.
  28. Holman W. L., Pae W. E., Teutenberg J. J. et al. INTERMACS: interval analysis of registry ata. J. Am. Coll. Surg. 2009; 208: 755-761.
  29. Rose E. A., Gelijns A. C., Moskowitz A. J. et al. Long-term mechanical left ventricular assistance for endstage heart failure. N. Engl. J. Med. 2001; 345: 1435-1443.
  30. Russell S. D., Miller L. W., Pagani F. D. Advanced heart failure: a call to action. Congest. Heart Fail. 2008; 14: 316-321.
  31. Lee D. K., Cheng R., Nguyen Tan T. et al. characterization apelin, the ligand for the APJ receptor. J. Neurochem. 2000; 74(1): 34-41.
  32. Chandrasekaran B., Dar O., McDonagh T. The role of apelin in cardiovascular function and heart failure. Eur. J. Heart Fail. 2008; 10: 725-732.
  33. Tatemoto K., Hosoya M., Habata Y. et al. Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem. Biophys. Res. Commun. 1998; 251(2): 471-476.
  34. Lee D. K., Saldivia V. R., Nguyen T. et al. B1 modification of-the terminal residue of apelin-13 antagonizes its hypotensive action. Endocrinology 2005; 146(1): 231-236.
  35. Szokodi I., Tavi P., Foldes G. et al. Apelin, the novel endogenous ligand of the orphan receptor APJ, regulates cardiac contractility. Circ. Res. 2002; 91(5): 434-440.
  36. Vickers C., Hales P., Kaushik V. et al. Hydrolysis of biological peptides by human Angiotensin-converting enzyme-related carboxypeptidase. J. Biol. Chem. 2002; 277(17): 14838-14843.
  37. Писаренко О. И., Шульженко В. С., Пелогейкина Ю. А. и др. Влияние экзогенного пептида апелина-12 на восстановление функции и метаболизма изолированного сердца крысы после ишемии. Кардиология 2010; 10: 44-49.
  38. Barondes S. H., Cooper D. N. W., Gitt M. A. et al. Galectins: structure and function of a large family of animal lectins. J. Biol. Chem. 1994; 269: 20807-20810.
  39. Yang R. Y., Rabinovich G. A., Liu F. T. Galectins: Structure, function, and therapeutic potential. Expert. Rev. Mol. Med. 2008; 10: e17.
  40. Zick Y., Eisenstein M., Goren R. A. et al. Role of galectin-8 as a modulator of cell adhesion and cell growth. Glycoconjugate J. 2004; 19: 517-526.
  41. Liu F. T., Patterson R. J., Wang J. L. Intracellular functions of galectins. Biochim. Biophys. Acta 2002; 1572: 263-273.
  42. Lok D., Van Der Meer P., Bruggink-André de la Porte P. et al. Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: daa from the DEAL-HF study. Clin. Res. Cardiol. 2010; 99(5): 323-328.
  43. Van Kimmenade R. R., Januzzi Jr. J. L., Ellinor P. T. et al. Utility of amino-terminal probrain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J. Am. Coll. Cardiol. 2006; 48: 1217-1224.
  44. Milting H., Ellinghaus P., Seewald M. et al. Plasma biomarkers of myocardial fibrosis and remodeling in terminal heart failure patients supported by mechanical circulatory support devices. J. Heart Lung Transplant. 2008; 27: 589-596.
  45. Всемирная организация здравоохранения. Доклад о состоянии здравоохранения в мире, 2007 г. Глобальная безопасность в области общественного здравоохранения в XXI веке - более безопасное будущее. Доступно на http:// www.who.int/whr/2007/whr07_ru.pdf.

Statistics

Views

Abstract - 39

Cited-By


Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Novoslobodskaya str 31c4., Moscow, 127005, Russian Federation

Managing Editor:

 

© 2018 "Consilium Medicum" Publishing house

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies